The expanded approval was based on the single-arm, non-randomized, open-label phase 4 PETITE-T1D study, which evaluated the safety and pharmacokinetics of teplizumab.

By targeting underlying synovitis, the novel intra-articular liraglutide formulation 4P004 aims to bridge the gap between transient symptom relief and disease modification in knee OA.

Dr Erica Schwartz, nominated to lead the US Centers for Disease Control and Prevention, is highly qualified, according to ...

Gabapentinoids are associated with an increased risk for drug poisoning, particularly in the short-term after initiation, according to a study published online ...

Treatment with satralizumab reduced the risk of new MOGAD relapse by 68% vs placebo. Positive results were announced from a phase 3 trial evaluating satralizumab for the treatment of myelin ...

Adults with IgA nephropathy treated with ravulizumab show significant proteinuria improvement as early as week 10.

Older adults with adenoma at prior colonoscopy more likely to experience CRC but risk exceeded by competing risks for non-CRC death.

No increase seen in incidence of major bleeding, adverse events, or serious adverse events compared with placebo.

Treatment with daraxonrasib significantly improves progression free survival and overall survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma. Topline results were ...

Phase 4 COMPARE trial data show Nuvaxovid was associated with lower reactogenicity and fewer daily activity disruptions than mNEXSPIKE.

The US Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies. Peptides are small chains of amino acids ...

Phase 3 KEYNOTE-B15 data demonstrate that perioperative enfortumab vedotin and pembrolizumab significantly improve EFS, OS, and pCR compared with standard chemotherapy.